Tesamorelin is currently in a confirmatory Phase 3 clinical trial for a serious metabolic disorder known as HIV-associated lipodystrophy.

Products

Click on one of the conditions below to find out more about the status of our programs.

Discovery Preclinical Phase 1 Phase 2 Phase 3 Confirmatory Phase 3
Pipeline
HIV-associated lipodystrophy completed completed completed completed completed underway
Growth hormone deficient abdominal obesity (GHDAO)* completed completed completed underway
Acute renal insufficiency completed underway
  underway : underway   completed : completed

Our product portfolio contains promising therapeutic products at various stages of development aimed at answering unmet medical needs in commercially attractive markets. Theratechnologies is currently focusing its resources on the development of tesamorelin in HIV-associated lipodystrophy.

*Study sponsored by the Massachusetts General Hospital through Dr. Steven Grinspoon